Puma Biotechnology

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2010-01-01

Employees: 185

Market Cap: $124.5M

Website: http://www.pumabiotechnology.com

Introduction: Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Clinical Trials

Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease

Phase 1

Completed

Conditions: Hepatic Insufficiency

Interventions: Drug: Neratinib (HKI-272)

First Posted Date: 2008-10-29

Last Posted Date: 2012-05-14

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 27

Registration Number: NCT00781430

Locations: 🇷🇺
Pfizer Investigational Site, Moscow, Russian Federation

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Phase 2

Completed

Conditions: Advanced Breast Cancer
Breast Cancer

Interventions: Drug: Neratinib
Drug: Lapatinib
Drug: Capecitabine

First Posted Date: 2008-10-22

Last Posted Date: 2018-08-09

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 233

Registration Number: NCT00777101

Locations: 🇿🇦
The Medical Oncology Centre of Rosebank, Johannesburg, Gauteng, South Africa
🇹🇭
Division of Medical Oncology, Department of Medicine, Bangkok-noi, Bangkok, Thailand
🇬🇧
Broomfield Hospital, Chelmsford, Essex, United Kingdom

and more 149 locations

Study Evaluating Safety And Tolerability, Solid Tumor

Phase 1

Completed

Conditions: Advanced Malignant Solid Tumors

Interventions: Drug: Neratinib
Drug: Paclitaxel

First Posted Date: 2008-10-08

Last Posted Date: 2018-11-19

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 10

Registration Number: NCT00768469

Locations: 🇯🇵
Investigational Site, Tokyo, Japan

Study Evaluating The Tolerability Of Multiple Doses Of HKI-272

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: neratinib

First Posted Date: 2008-09-23

Last Posted Date: 2012-05-14

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 50

Registration Number: NCT00757809

Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: Neratinib
Drug: Capecitabine

First Posted Date: 2008-08-26

Last Posted Date: 2018-09-05

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 105

Registration Number: NCT00741260

Locations: 🇦🇺
Border Medical Oncology, Wodonga, Victoria, Australia
🇭🇷
University Hospital Center Zagreb Department of Oncology, Zagreb, Croatia
🇷🇺
Saint-Petersburg State Medical University n.a. acad. I.P. Pavlov, Laboratory of Thoracic Oncology of Pulmonology Research Institute, Saint Petersburg, Russian Federation

and more 34 locations

Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: neratinib
Other: Placebo
Drug: Moxifloxacin

First Posted Date: 2008-07-02

Last Posted Date: 2012-05-14

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 60

Registration Number: NCT00708903

Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer
Advanced Malignant Solid Tumors

Interventions: Drug: neratinib
Drug: vinorelbine

First Posted Date: 2008-06-27

Last Posted Date: 2018-08-09

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 92

Registration Number: NCT00706030

Locations: 🇺🇸
Albert Einstein Cancer Center, Bronx, New York, United States
🇫🇷
Centre Paul Papin, Angers, France
🇪🇸
Centro Oncologico de Galicia, A Coruña, Spain

and more 32 locations

Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: neratinib

First Posted Date: 2007-10-29

Last Posted Date: 2012-05-14

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 6

Registration Number: NCT00550212

Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy

First Posted Date: 2007-07-10

Last Posted Date: 2012-05-14

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 36

Registration Number: NCT00498745

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Phase 1

Completed

Conditions: Advanced Breast Cancer
Advanced Malignant Solid Tumors
Breast Neoplasms

Interventions: Drug: HKI-272
Drug: Paclitaxel

First Posted Date: 2007-03-09

Last Posted Date: 2018-07-26

Lead Sponsor: Puma Biotechnology, Inc.

Target Recruit Count: 110

Registration Number: NCT00445458

Locations: 🇺🇸
Boston University Medical Center, Boston, Massachusetts, United States
🇺🇸
Mid-Michigan Physicians-HOS Division, Lansing, Michigan, United States
🇨🇦
Princess Margaret Hospital University Health Network, Toronto, Ontario, Canada

and more 29 locations

Home Terms & Conditions Privacy Policy